5 citations
,
December 2023 in “Clinical Case Reports”
This article suggests considering biologics to stabilize inflammation in moderate to severe folliculitis decalvans, although it reports no new clinical results.
This case report describes how changing treatment from adalimumab to guselkumab successfully controlled both pustulotic arthro-osteitis and paradoxical skin reactions in a patient with palmoplantar pustulosis.
This study analyzed adverse event reports from the FDA database and found that drugs such as immunomodulatory agents, monoclonalantibodies, minoxidil, contraceptives, and anti-TNF drugs are frequently associated with hair loss, suggesting guidance for dermatologists in identifying common medications linked to alopecia.
In this study, nearly 5% of anti-TNF-treated patients with IBD developed psoriasiform skin lesions, with smoking identified as a main risk factor, and ustekinumab proved highly effective in severe cases.
60 citations
,
September 2013 in “Alimentary Pharmacology & Therapeutics”
This review discusses the dermatological adverse events from immunosuppressive and anti-TNF therapy in IBD, finding increased risks of non-melanoma skin cancer and other skin conditions, and recommends regular cancer screening.
The conversation discusses the potential for developing a biologic "DHT sponge" to neutralize DHT in the bloodstream as a treatment for hair loss, suggesting it could be more targeted and have fewer side effects than current treatments like finasteride and dutasteride. Concerns include the complexity, cost, and potential side effects of such a treatment, as well as skepticism about its feasibility and market interest.
Prolactin may contribute to hair loss, but targeting its receptor won't cure androgenetic alopecia. ABS-201 could be a useful alternative or adjuvant therapy, similar to JAK inhibitors, but not more effective than HMI-115.